ZURICH, June 30 (Reuters) - The chairman of Swiss drugmaker Novartis expects Alcon to be valued at between $20 billion and $30 billion when the opthalmic devices unit is spun off to shareholders next year, he said in an interview with Finanz und Wirtschaft. "Just how much it's ultimately going to be will be determined when we know how debt and other things will be quantified," Joerg Reinhardt told the Swiss financial newspaper.
from Reuters: Company News https://ift.tt/2tQhYKg
via IFTTT
0 comments:
Post a Comment